BUDGET IMPACT ANALYSIS OF BOTULINUM TOXIN A THERAPY FOR UPPER LIMB SPASTICITY IN HONG KONG
Author(s)
Dinet J1, Nai Mo LAM E2, Gabriel S1
1IPSEN Pharma, Boulogne-Billancourt, France, 2Beaufour Ipsen Tianjin Pharmaceutical Co, TIANJIN, China
OBJECTIVES: Upper limb spasticity (ULS) secondary to stroke has a considerable patient and caregiver burden, particularly with regards to pain, activities of daily living and mobility. Botulinum neurotoxin-A (BoNT-A) injections are effective in treating ULS. We aimed to calculate annual cost per-patient basis and the expected overall annual budget impact in Hong Kong using static and dynamic market share scenarios.METHODS: A budget impact model for BoNT-A use, adopting a Hong Kong healthcare system perspective, was developed. Two market-share scenarios were modelled over 5 years. While the static scenario assumed current market shares (abobotulinumtoxinA, 24%; onabotulinumtoxinA, 76%) to remain constant over time, the dynamic scenario assumed market share of abobotulinumtoxinA to rise up to 65% across 5 years. Epidemiologic data inputs were sourced from the most recently published literature, unit costs for BoNT-As, healthcare resources use from physicians working in Hong Kong, and market share assumptions from IMS Health (Market Sizing). Equivalence of the 2 BoNTAs in terms of efficacy and safety is assumed but the units of abobotulinumtoxinA are specific to the preparation and are not interchangeable with other preparations of botulinum toxin. RESULTS: Annual cost per ULS patient were 59 907 HKD, and 76 888 HKD respectively, with prescribing patterns following SmPC recommendations for abobotulinumtoxinA and onabotulinumtoxinA. The annual budget impact was decreased by between 28 731 553 HKD in year 2 and 111 142 610 HKD in year 5 by shifting the market share to abobotulinumtoxinA. Sensitivity analyses showed that time to re-injection, and dose per injection for both toxins were the most influential parameters on budget impact, impacting both drug acquisition costs and physician visits.CONCLUSIONS: Increased use of abobotulinumtoxinA relative to onabotulinumtoxinA could potentially reduce the total cost of treating ULS patients in Hong Kong.
Conference/Value in Health Info
2015-05, ISPOR 2015, Philadelphia, PA, USA
Value in Health, Vol. 18, No. 3 (May 2015)
Code
PMS26
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Musculoskeletal Disorders